All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Cilta-Cel Generates OS Benefit in R/R Myeloma After 1 Prior Therapy

July 2nd 2024

Cilta-cel improved overall survival vs standard regimens in relapsed/lenalidomide-refractory multiple myeloma after 1 prior line of therapy.

FDA Receives BLA Resubmission for Cosibelimab in Advanced CSCC

July 2nd 2024

The FDA has received a biologics license application resubmission for cosibelimab in locally advanced or metastatic cutaneous squamous cell carcinoma.

OncLive Honors 15 Cancer Care Pioneers

July 2nd 2024

OncLive honors 15 oncology leaders with the 2024 Giants of Cancer Care awards for their innovations in improving patient outcomes.

Fox Chase Cancer Center Celebrates a $20 Million Legacy of Philanthropy from Marvin and Concetta Greenberg

July 2nd 2024

Fox Chase Cancer Center celebrated a gift of $10.8 million from the Estate of Concetta “Chet” Greenberg, an ardent champion of cancer research during her life.

Dual mTORC1/mTORC2 Inhibitor Sapanisertib Shows Promise in Combination Regimens for Solid Tumors

July 2nd 2024

Vivek Subbiah, MD, details the rationale for combining sapanisertib with ziv-aflibercept or metformin and next steps for mTOR inhibitors in solid tumors.

Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer

July 1st 2024

The EMA recommends durvalumab plus chemotherapy, followed by olaparib and durvalumab for pMMR endometrial cancer, and single-agent durvalumab for dMMR disease.

Durvalumab Plus Chemo Maintains OS Benefit in Advanced Biliary Tract Cancer

July 1st 2024

Durvalumab plus chemotherapy sustained an overall survival benefit vs chemotherapy alone in locally advanced or metastatic biliary tract cancer.

Pembrolizumab Plus Bevacizumab/CAPOX Yields Responses in pMMR/MSS mCRC With High TILs

July 1st 2024

Pembrolizumab plus bevacizumab and CAPOX produced responses in pMMR/MSS metastatic colorectal cancer with high immune infiltrate.

TAP Score and CPS May Be Viable for PD-L1 Expression Measurement in Advanced Gastric Cancers

July 1st 2024

Concordance between TAP score and CPS at matched thresholds indicate their viability for assessing PD-L1 expression in advanced gastric cancers.

Nivolumab/Ipilimumab/Radiation Combo Produces Responses in Locally Advanced Rectal Cancer

July 1st 2024

The EA2201 trial evaluated nivolumab, ipilimumab, and short-course radiation therapy in patients with locally advanced rectal cancer.

Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status

July 1st 2024

Botensilimab and balstilimab demonstrated pathological responses across subsets of patients with resectable colon cancer.

Anti-Inflammatory Drug Celecoxib Could Reduce Risk of Colon Cancer Recurrence For a Subset of Patients

July 1st 2024

A study found stage 3 colon cancer patients with PIK3CA mutations taking celecoxib post-surgery had longer survival and disease-free intervals.

FDA Green Lights Companion Diagnostic for Niraparib Plus Abiraterone Acetate in BRCA+ mCRPC

July 1st 2024

The FDA has approved a companion diagnostic for niraparib plus abiraterone acetate in BRCA-mutated metastatic castration-resistant prostate cancer.

Belantamab Mafodotin–Based Combo Boosts PFS in Difficult-to-Treat R/R Myeloma Subgroups

July 1st 2024

María-Victoria Mateos, MD, PhD, discusses subgroup results for belantamab mafodotin plus bortezomib/dexamethasone in relapsed/refractory myeloma

Revisit Every OncLive On Air Episode From June 2024

July 1st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.

ERK Inhibition Does Not Enhance BEACON Regimen Efficacy in Untreated BRAF V600E–Mutated CRC

June 30th 2024

Aparna Parikh, MD, discusses key findings from the HERKULES-3 study and what the future of the BRAF-mutated mCRC treatment paradigm may look like.

postMONARCH Meets Primary End Point of Improvement of PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

June 29th 2024

Kevin Kalinsky, MD, MS, discusses the outcomes of the postMONARCH study in patients with HR+/HER2– breast cancer following disease progression.

TRANSMET Regimen Proves Safe, Feasible for Definitively Unresectable CRC Liver Metastasis

June 28th 2024

Liver transplantation plus chemotherapy demonstrated no concerning safety signals or long-term deterioration in QOL in patients with definitively unresectable CRC liver metastasis.

Switch Ramucirumab/Paclitaxel Maintenance Yields Favorable Outcomes in HER2– Gastric Cancer

June 28th 2024

Switch ramucirumab/paclitaxel maintenance improved PFS and OS outcomes vs chemotherapy continuation in HER2-negative gastric or GEJ cancer.

TAS-102 Followed By Regorafenib Identified As Optimal Treatment Sequence in Pretreated mCRC

June 28th 2024

TAS-102 followed by regorafenib is an optimal sequence vs regorafenib followed by TAS-102 in select patients with metastatic colorectal cancer.

NEXT PAGE
PREVIOUS PAGE